Table 1.
Epidemiological and cost inputs for decision analysis models.
| Parameter | Value | Source |
|---|---|---|
| Number of Black Non-Hispanics in U.S. | [25] | |
| 60 to 64 | 2,191,197 | |
| 65 to 69 | 1,642,788 | |
| 70 to 74 | 1,082,966 | |
| 75 to 79 | 749,209 | |
| 80 to 84 | 493,406 | |
| Vaccine coverage under status quo | [20] | |
| 60 to 64 | 12.7% | |
| At least 65 | 14.1% | |
| Vaccine coverage under health equity | [20] | |
| 60 to 64 | 25.1% | |
| At least 65 | 38.3% | |
| Incidence of herpes zoster per 1000-person years | [2,27] | |
| 60 to 69 | 5.90 | |
| 70 to 79 | 7.76 | |
| At least 80 | 9.76 | |
| Initial vaccine effectiveness | [15,27] | |
| 60 | 69.4% | |
| 65 | 62.7% | |
| 70 | 53.3% | |
| 75 | 41.2% | |
| Background mortality rate per 100,000 | [26] | |
| 60 to 64 | 1571.1 | |
| 65 to 69 | 2069.7 | |
| 70 to 74 | 2694.9 | |
| 75 to 79 | 4311.4 | |
| 80 to 84 | 6427.4 | |
| At least 85 | 12,364.4 | |
| Direct costs for uncomplicated herpes zoster | [7,28] | |
| 60 to 64 | $1510 | |
| 65 to 69 | $1628 | |
| 70 to 79 | $2153 | |
| 80 and over | $2877 | |
| Direct costs for herpes zoster with PHN | [7,28] | |
| 60 to 64 | $6680 | |
| 65 to 69 | $7027 | |
| 70 to 79 | $9311 | |
| 80 and over | $12,142 | |
| Direct costs for patients with complications | [9,28] | |
| Ocular | $4275 | |
| Neurologic | $10,136 | |
| Skin | $10,137 | |
| Other | $10,712 | |
| Indirect costs for patients with herpes zoster | [9,30] | |
| 60 to 64 | $2434 | |
| 65 to 69 | $936 | |
| 70 to 74 | $552 | |
| Over 75 | $233 |
Notes: PHN = post herpetic neuralgia; U.S. = United States.